Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to determine the expression of prostate specific membrane
antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor
(AR)-positive metastatic breast cancer, and to determine its role in resistance to the
anti-androgen, bicalutamide. The investigators hypothesize that PSMA expression will
correlate with resistance to anti-androgen therapies, as has been documented in prostate
cancer, and this can be used to select patients most likely to benefit from these therapies
in future clinical trials. 15 people with HER2-negative, AR-positive metastatic breast cancer
will be enrolled and be on study for about 3 days.